Merck settles tax dispute with IRS for $2.3 billion

Share this article:
Merck has entered an agreement to settle its previously disclosed tax disputes with the Internal Revenue service for $2.3 billion. The settlement essentially brings to a close the IRS’s examination of the company for the period 1993-2001, the Whitehouse Station, NJ drugmaker said in a statement issued today. The figure of $2.3 billion will cover federal tax and net interest after deductions and penalties, Merck said. The IRS' examination of years subsequent to 2001 remains open. Merck announced in November that it faced potential tax liabilities totaling $5.58 billion from US and Canadian authorities related to disputes over accounting for past transactions.
Share this article:

Email Newsletters

More in News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.